The company maintains a zero-revenue profile with quarterly SG&A expenses escalating to $456.5K in 2026Q1, reflecting the mounting costs of maintaining a public listing.
| Sales/Revenue | 0 | - | - |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | - | - |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 1.26M | 1.2M | 704 |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 1.26M | 1.2M | 704 |
| SG&A % of Revenue | - | - | - |
| Research & Development | 0 | - | - |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | - | - |
| Operating Income | -1.26M | -1.2M | -703 |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -169983.5% | - |
| EBITDA | -1.26M | -1.2M | 1 |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -99999900% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 704 |
| EBIT | -1.26M | -1.2M | -703 |
| Net Interest Income | 7.78M | 8.48M | 1.59M |
| Interest Income | 7.78M | 8.48M | 1.59M |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | 0 | - | - |
| Pretax Income | 6.62M | 7.29M | 2.66K |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% |
| Net Income | 6.62M | 7.29M | 2.66K |
| Net Margin % | - | - | - |
| Net Income Growth % | - | 273607.25% | - |
| Net Income (Continuing) | 6.62M | 7.29M | 2.66K |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | 0.34 | 0.30 | 0.05 |
| EPS Growth % | - | 453.51% | - |
| EPS (Basic) | - | 0.30 | 0.05 |
| Diluted Shares Outstanding | 19.2M | 19.2M | 24.58M |
| Basic Shares Outstanding | 19.2M | 19.2M | 24.58M |
| Dividend Payout Ratio | - | - | - |
Liquidation and deal execution
As reported in recent financial filings, OACCW's quarterly SG&A expenses have trended upward to $456.5K in 2026Q1, reflecting the mounting costs of maintaining a public listing and conducting due diligence on potential biopharmaceutical targets while the entity remains in a pre-revenue, shell-company state.
The steady rise in operating expenses suggests that the search for a viable business combination is becoming increasingly resource-intensive. Investors should monitor whether these costs, which are currently outpacing initial search-phase projections, necessitate additional sponsor-led capital injections to sustain operations through the remaining lifecycle.
Based on the company's income statements, the reported net income of $1.4M in 2026Q1 is entirely decoupled from operational performance, as it stems from non-operating interest income generated by the trust account rather than any underlying business activity or revenue-generating operations.
This disconnect highlights the binary nature of the entity, where net income is a function of interest rate environments rather than corporate efficiency. Analysts should focus on the operating loss trajectory, which indicates the true burn rate of the vehicle, rather than the headline net income figures.
According to the provided financial data, the company's cash position of $1.43M relative to its quarterly burn rate suggests a narrowing window for deal completion, raising concerns that the sponsor may face pressure to finalize an acquisition before the liquidation deadline forces a return of capital.
The risk of 'deal pressure' is significant, as the need to deploy capital may lead to the selection of a sub-optimal target to avoid liquidation. Investors should be wary of the potential for value-destructive acquisitions driven by the expiration of the search clock rather than fundamental clinical merit.
As indicated by the income statement history, OACCW maintains a zero-revenue profile, meaning there is no operating leverage to analyze until a business combination occurs and the entity transitions into an operational biopharmaceutical or medical device firm.
The current structure is purely transactional, and the lack of revenue means that all SG&A costs represent a direct drain on the trust account's value. Future analysis must pivot entirely to the target company's cost structure once a merger is successfully executed.
Quick answers to the most common questions about buying OACCW stock.
Oaktree Acquisition Corp. III Life Sciences (OACCW) is profitable, generating $7.3M in net income for the fiscal year ending 2025.